Trials / Completed
CompletedNCT00563810
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029
An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a multiple dose study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational new drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MYO-029 |
Timeline
- Start date
- 2004-10-01
- Completion
- 2006-04-01
- First posted
- 2007-11-26
- Last updated
- 2007-11-26
Source: ClinicalTrials.gov record NCT00563810. Inclusion in this directory is not an endorsement.